good supplier High Quality 245765-41-7 low price Ozenoxacin

Superiority:

good supplier High Quality 245765-41-7 low price Ozenoxacin

Ozesha Star, a quinolone antimicrobial developed by Ferrer Internacional Co., Ltd. of Spain, purchased by Medimetriks Pharmaceuticals Pharmaceuticals of the United States and granted exclusive U.S. commercialization rights, was approved by Japan's Ministry of Health, Labour and Welfare in September 2015 as the world's first approved new molecular entity, and was approved for listing by the U.S. FDA on December 11, 2017. Ozesha star acts as a mechanism for inhibiting bacterial DNA replication enzymes, DNA protractic enzyme A and topological isomer enzyme IV. Ozesha is the third non-fluoroquinolone-like antimicrobial drug approved worldwide, after Nenosha and Garesa. Clinical trials have used Ozesha star to treat skin and soft tissue infections, with better efficacy than morphine, with no significant adverse reactions. The inhibition effect of Ozesha star on MRSA, methicillin-sensitive phenoccus (MSSA), oxyfluorosa-resistant phenoccus, etc. was significantly stronger than that of nafluoosa, oxyfluorosa, levonolosa, chlorincomycin, erythromycin and gygotomycin. Ozesha star sterilization activity is strong, can become a shortened course of treatment, and has a good clinical application prospects of quinolones.
Indications
Used to treat pustules from infection with Staphylococcus aureus or purulent streptococcus in patients aged two months or older.